News|Articles|April 15, 2022
NeurologyLive® Friday 5 — April 15, 2022
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 15, 2022.
Advertisement
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Jennifer Frontera, MD: Relaying Messages About Long-Term Effects of COVID-19
The professor of neurology at NYU Langone Grossman School of Medicine broke down the knowns and unknowns about long-term changes related to COVID-19, their legitimacy, and their associations with neurodegenerative disorders.
2: Peers & Perspectives: The Role of Nonpharmacologic Treatments in Narcolepsy
In Episode 6 of the NeurologyLive® Peers & Perspectives series, "Improving Diagnosis and Patient Outcomes in Narcolepsy ," Russell Rosenberg, PhD, DABSM, and Margaret Park, MD, explore the use of nonpharmacologic treatment approaches for the management of narcolepsy.
3: NeuroVoices: Justin Klee, Josh Cohen on Building AMX0035’s Case as the Next ALS Treatment
Following their data presentation on AMX0035 at AAN 2022 and the FDA Advisory Committee vote on the phase 2/3 trial data, Justin Klee and Josh Cohen, the cofounders and cochief operating officers of Amylyx Pharmaceuticals, shared their perspectives on the agent.
4: The Progress Made in Stem Cell Therapy, Regenerative Medicine: Peter J. McAllister, MD, FAAN
The medical director and chief medical officer of the New England Center for Neurology and Headache discussed notable data from the STEMTRA trial, and the progress made in the field of regenerative medicine.
5: ACD Score Proves Valuable in Estimating Long-Term Survival in Status Epilepticus
New neurological deficits were a predictor of long-term survival regardless of the status epilepticus cause and were associated with a 5-fold increase in the odds of death 2 years after status epilepticus diagnosis.
—————————————————
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
3
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
4
This Week on NeurologyLive® — September 15, 2025
5